![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Inflammatory Bowel Diseases |
Free Subscription
3 BMC Gastroenterol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Inflammatory Bowel Diseases is free of charge.
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients
with inflammatory bowel disease: a systematic review and meta-analysis.
BMC Gastroenterol. 2022;22:291.
PubMed
Abstract available
Physical activity measured by accelerometry in paediatric and young adult
patients with inflammatory bowel disease.
BMC Gastroenterol. 2022;22:290.
PubMed
Abstract available
Prevalence and factors associated with fatigue in patients with ulcerative
colitis in China: a cross-sectional study.
BMC Gastroenterol. 2022;22:281.
PubMed
Abstract available
Impatience with Inpatients: Are Hospitalization Rates Declining for IBD Patients?
Dig Dis Sci. 2022;67:1927-1929.
PubMed
Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients
with Inflammatory Bowel Diseases.
Dig Dis Sci. 2022;67:2039-2048.
PubMed
Abstract available
UK IBD Twin Registry: Concordance and Environmental Risk Factors of Twins with
IBD.
Dig Dis Sci. 2022;67:2444-2450.
PubMed
Abstract available
Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic
Pouchitis? A Systematic Review.
Dig Dis Sci. 2022;67:1948-1955.
PubMed
Abstract available
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-alpha
Antagonists in Patients with Inflammatory Bowel Diseases.
Dig Dis Sci. 2022;67:2510-2516.
PubMed
Abstract available
Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and
Magnetic Resonance Enterography in Assessment of Crohn's Disease Activity: A
Comparison with Surgical Histopathology Analysis.
Dig Dis Sci. 2022;67:2492-2502.
PubMed
Abstract available
Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier,
and Attenuates Inflammatory Cells in Crohn's Disease.
Dig Dis Sci. 2022;67:2143-2157.
PubMed
Abstract available
Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased
Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Dig Dis Sci. 2022;67:2480-2484.
PubMed
Abstract available
Adiponectin Alleviates Intestinal Fibrosis by Enhancing AMP-Activated Protein
Kinase Phosphorylation.
Dig Dis Sci. 2022;67:2232-2243.
PubMed
Abstract available
Increased Fecal Bile Acid Excretion in a Significant Subset of Patients with
Other Inflammatory Diarrheal Diseases.
Dig Dis Sci. 2021 Apr 22. pii: 10.1007/s10620-021-06993.
PubMed
Abstract available
Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size
does not fit all'.
Eur J Gastroenterol Hepatol. 2022;34:808.
PubMed
Controversy of Preoperative Exposure to Tumor Necrosis Factor Inhibitors in
Surgical and Infectious Complications of Inflammatory Bowel Disease.
Gastroenterology. 2022 Jun 1. pii: S0016-5085(22)00588.
PubMed
Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative
colitis: development of a novel simplified histological score for monitoring
mucosal healing and predicting clinical outcomes and its applicability in an
artificial intelligenc
Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.
PubMed
Reverse translation approach generates a signature of penetrating fibrosis in
Crohn's disease that is associated with anti-TNF response.
Gut. 2022;71:1289-1301.
PubMed
Abstract available
Eating Disorders: Diagnosis and Management Considerations for the IBD Practice.
Inflamm Bowel Dis. 2022;28:936-946.
PubMed
Peripartum Exposure to Biologic Therapy Does Not Impact Postpartum Wound Healing
in Women With IBD.
Inflamm Bowel Dis. 2022;28:843-849.
PubMed
Abstract available
IBD in the Postpartum Period: Spotlight on Maternal Outcomes.
Inflamm Bowel Dis. 2022;28:980-981.
PubMed
What Is a Flare? The Manitoba Living With IBD Study.
Inflamm Bowel Dis. 2022;28:862-869.
PubMed
Abstract available
The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory
Bowel Diseases: Nationwide Analysis.
Inflamm Bowel Dis. 2022;28:878-887.
PubMed
Abstract available
Machine Learning Predictive Outcomes Modeling in Inflammatory Bowel Diseases.
Inflamm Bowel Dis. 2022;28:819-829.
PubMed
Abstract available
Health Care Costs and Resource Utilization Among Patients With Crohn's Disease
With and Without Perianal Fistula.
Inflamm Bowel Dis. 2022;28:870-877.
PubMed
Abstract available
Efficacy of Ustekinumab in Crohn's Disease With and Without Concurrent Autoimmune
Skin Disease.
Inflamm Bowel Dis. 2022;28:895-904.
PubMed
Abstract available
Treatment of Fistulizing Perianal Crohn's Disease by Autologous Microfat Enriched
With Adipose-Derived Regenerative Cells.
Inflamm Bowel Dis. 2022;28:967-970.
PubMed
Long-term Disease Behavior and Surgical Intervention Analysis in Hospitalized
Patients With Crohn's Disease in China: A Retrospective Cohort Study.
Inflamm Bowel Dis. 2022;28.
PubMed
Abstract available
Granulomatous Pneumonia and Liver Lesions Associated With Crohn's Disease.
Inflamm Bowel Dis. 2022;28:e78-e79.
PubMed
Protein Kinase CK2 Maintains Reciprocal Balance Between Th17 and Treg Cells in
the Pathogenesis of UC.
Inflamm Bowel Dis. 2022;28:830-842.
PubMed
Abstract available
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and
Development of Vaccine-Related Adverse Events: A Survey From China.
Inflamm Bowel Dis. 2022 Jun 6. pii: 6603234. doi: 10.1093.
PubMed
Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive
Ulcerative Colitis Patients: Results of a Phase II, Randomized,
Placebo-Controlled Trial.
Inflamm Bowel Dis. 2022 Jun 4. pii: 6602039. doi: 10.1093.
PubMed
Abstract available
COVID-19 as a Trigger for De Novo Crohn's Disease.
Inflamm Bowel Dis. 2022;28:e76-e77.
PubMed
Pulmonary Infection Due to Reactivation of Latent Epstein-Barr Virus in a Patient
With Crohn's Disease Treated With Infliximab.
Inflamm Bowel Dis. 2022;28:e80-e81.
PubMed
Identifying the Presence, Activity, and Status of Extraintestinal Manifestations
of Inflammatory Bowel Disease Using Natural Language Processing of Clinical
Notes.
Inflamm Bowel Dis. 2022 Jun 3. pii: 6601382. doi: 10.1093.
PubMed
Abstract available
Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results
from a Multicenter, Prospective Study in China.
Inflamm Bowel Dis. 2022;28.
PubMed
Caveolin-1 Alleviates Crohn's Disease-induced Intestinal Fibrosis by Inhibiting
Fibroblasts Autophagy Through Modulating Sequestosome 1.
Inflamm Bowel Dis. 2022;28:923-935.
PubMed
Abstract available
Challenging the Surge of Inflammatory Bowel Disease: The Role of the China
Crohn's and Colitis Foundation in the Healthcare Landscape of Inflammatory Bowel
Disease.
Inflamm Bowel Dis. 2022;28.
PubMed
Abstract available
Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early
Response to Anti-TNF Therapy in Patients With Crohn's Disease: A Pilot Study.
Inflamm Bowel Dis. 2022;28.
PubMed
Abstract available
A Case of Behcet's Disease With Hepatic Lesions Misdiagnosed as Crohn's Disease.
Inflamm Bowel Dis. 2022;28:e86-e87.
PubMed
Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease
After Ileocecal Resection: A Multicenter Study Comparing the East and West.
Inflamm Bowel Dis. 2022;28.
PubMed
Abstract available
Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients
With Crohn's Disease: A Hospital-Based Cohort Study in China.
Inflamm Bowel Dis. 2022;28.
PubMed
Abstract available
Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes
in Children with Ulcerative Colitis.
J Crohns Colitis. 2022 Jun 4. pii: 6602063. doi: 10.1093.
PubMed
Abstract available
Faecal metabolomics in paediatric inflammatory bowel disease: a systematic
review.
J Crohns Colitis. 2022 Jun 9. pii: 6605030. doi: 10.1093.
PubMed
Abstract available
Risankizumab as induction therapy for Crohn's disease: results from the phase 3
ADVANCE and MOTIVATE induction trials.
Lancet. 2022;399:2015-2030.
PubMed
Abstract available
Risankizumab for Crohn's disease.
Lancet. 2022;399:1992-1993.
PubMed
Risankizumab as maintenance therapy for moderately to severely active Crohn's
disease: results from the multicentre, randomised, double-blind,
placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet. 2022;399:2031-2046.
PubMed
Abstract available
Sweet's syndrome and Crohn's disease diagnosed simultaneously.
Lancet. 2022;399:2155.
PubMed
Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease.
PLoS One. 2022;17:e0269561.
PubMed
Abstract available
[KARLOTTA (Kids + Adolescents Research Learning On Tablet Teaching Aachen) -
randomized controlled pilot study for the implementation of a digital educational
app with game of skill for pediatric patients with inflammatory bowel disease].
Z Gastroenterol. 2022 Jun 7. doi: 10.1055/a-1799-9267.
PubMed
Abstract available
Z Gastroenterol. 2022;60:1038-1039.
PubMed
[Position paper on reporting of intestinal ultrasound findings in patients with
inflammatory bowel disease].
Z Gastroenterol. 2022;60:978-990.
PubMed
Abstract available
[Bowel resections for Crohn's disease: developments over the last three decades].
Z Gastroenterol. 2022;60:927-936.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by